申请人:AbbVie Deutschland GmbH & Co. KG
公开号:US20160304527A1
公开(公告)日:2016-10-20
Compounds of formula (I)
and pharmaceutically acceptable salts thereof, wherein R
1
, R
2
, R
3
, R
4
, L
1
and G
1
are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the γ-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
具有化学式(I)及其药用可接受的盐的化合物,其中R1、R2、R3、R4、L1和G1如规范中定义的那样,对于治疗由γ-氨基丁酸B(GABA-B)受体的正向变构调节预防或改善的症状或疾病是有用的。描述了制备这些化合物的方法。还描述了具有化学式(I)的化合物的药物组合物,以及使用这些化合物和组合物的方法。